Pardes Biosciences Stock Current Valuation
Valuation analysis of Pardes Biosciences helps investors to measure Pardes Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Pardes Biosciences Company Current Valuation Analysis
Pardes Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pardes Biosciences Current Valuation | (22.1 M) |
Most of Pardes Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pardes Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Pardes Biosciences has a Current Valuation of (22.1 Million). This is 100.15% lower than that of the Biotechnology sector and 100.48% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.13% higher than that of the company.
Pardes Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pardes Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pardes Biosciences could also be used in its relative valuation, which is a method of valuing Pardes Biosciences by comparing valuation metrics of similar companies.Pardes Biosciences is currently under evaluation in current valuation category among its peers.
Pardes Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | (22.1 M) | |||
| Shares Outstanding | 62.01 M | |||
| Shares Owned By Insiders | 13.47 % | |||
| Shares Owned By Institutions | 72.05 % | |||
| Number Of Shares Shorted | 874.35 K | |||
| Price To Book | 0.37 X | |||
| EBITDA | (99.82 M) | |||
| Net Income | (96.63 M) | |||
| Cash And Equivalents | 228.6 M | |||
| Cash Per Share | 3.67 X | |||
| Current Ratio | 20.84 X | |||
| Book Value Per Share | 2.57 X | |||
| Cash Flow From Operations | (71.98 M) | |||
| Short Ratio | 1.09 X | |||
| Earnings Per Share | (1.28) X | |||
| Target Price | 1.25 | |||
| Number Of Employees | 57 | |||
| Beta | 0.42 | |||
| Market Capitalization | 133.95 M | |||
| Total Asset | 200.62 M | |||
| Retained Earnings | (148.16 M) | |||
| Working Capital | 179.98 M | |||
| Z Score | -1.6 | |||
| Net Asset | 200.62 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Pardes Stock
If you are still planning to invest in Pardes Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pardes Biosciences' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |